Meta-analysis of 5 phase III RCTs found that anti-CGRP antibodies helped 44% more migraine patients transition from medication overuse to non-overuse status, with the strongest effect in triptan overusers (71% higher reversal rate).
RR 1.71 for triptan overuse reversalCGRP antibodies were most effective at helping triptan overusers transition to non-overuse status in meta-analysis of 5 RCTs
What the researchers found
Anti-CGRP antibodies increased transition from medication overuse to non-overuse status by 44% overall (RR: 1.44), with the strongest effect in triptan overusers (RR: 1.71) but no significant effect for simple analgesic overusers.
Why it matters
Medication overuse headache affects up to 2% of the general population and is notoriously difficult to treat. Knowing that CGRP antibodies can help patients break the overuse cycle — particularly for triptan users — gives clinicians a specific, evidence-based intervention for this challenging condition.
The numbers in context
The analysis included phase 3 RCTs. Patients overusing triptans responded most effectively to anti-CGRP antibody treatment.
How the study worked
Systematic review and meta-analysis of 5 phase III RCTs from PubMed (January 2013 - September 2023). Included eptinezumab, fremanezumab, galcanezumab, and erenumab. Analyzed by acute headache medication categories: triptans, simple analgesics, and multiple drugs.
Who was studied
Patients with episodic or chronic migraine and medication overuse
What this study cannot tell us
Only 5 studies met inclusion criteria. The medication overuse analyses were secondary outcomes in trials designed for other primary endpoints. The meta-analysis couldn't distinguish between the four CGRP antibodies. The lack of effect on simple analgesic overuse needs explanation.
How to read the evidence
Moderate to strong evidence from meta-analysis of phase III RCTs. Consistent direction of effect across studies, though medication overuse was typically a secondary outcome.
When this study was published
Published in 2024. Provides the most current meta-analytic evidence on CGRP antibodies and medication overuse.
The bigger picture
This meta-analysis reveals that CGRP antibodies don't just reduce migraine frequency — they specifically address the medication overuse complication that plagues many chronic migraine patients. The differential effect by medication type (strong for triptans, weak for analgesics) provides actionable clinical guidance.
Questions still open
- Why are CGRP antibodies less effective at reducing simple analgesic overuse compared to triptan overuse?
- Which specific CGRP antibody is most effective for medication overuse reversal?
- Should CGRP antibodies be used specifically as first-line treatment for medication overuse headache?
Common questions
What is medication overuse headache?
Why did CGRP antibodies help triptan overusers more than analgesic overusers?
Read the original research
The transition of medication overuse status by acute medication categories in episodic or chronic migraine patients to non-overuse status after receiving anti-CGRP monoclonal antibodies: a systematic review and meta-analysis of phase 3 randomized control trial.
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 45(9), 4451-4462
Citation
Sirilertmekasakul, Chananchida; Panto, Akkanat; Lekhalawan, Pattanan; Panyarachun, Pariyada; Jindasakchai, Porpim; Rattanawong, Wanakorn. (2024). The transition of medication overuse status by acute medication categories in episodic or chronic migraine patients to non-overuse status after receiving anti-CGRP monoclonal antibodies: a systematic review and meta-analysis of phase 3 randomized control trial.. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 45(9), 4451-4462. https://doi.org/10.1007/s10072-024-07496-7